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This is a case presentation and discussion of extensive vitiligo in a
44-year-old woman who was treated with monobenzone who had
previously failed repigmentation therapy with psoralen-ultra violet A
therapy.
Case Report
The patient is a 44-year-old woman of Portuguese descent who
first started experiencing depigmentation of her skin at age 14. The
patient was treated with oral psoralen-UltraViolet-A(PUVA) treat
ment for 2 years with partial repigmentation of the affected areas.
Additional therapy was performed intermittently between the ages
of 23 to 25 years with limited response. Due to pregnancy, the
patient discontinued treatment when she was 26. During this time
her vitiligo continued to worsen. Two years after her pregnancy the
patient began to experience a rapid progression of her vitiligo. The
patient was then evaluated for further PUVA therapy. On examina
tion it was noted that her vitiligo was extensive, involving more than
60% ofher body. This included highly visible areas around her eyes,
cheeks and mouth, in addition to her body and extremities. Further
more, the patient reported that sites of old repigmentation were
irregular and hyperpigmented even 15 years after initial treatment.
The patient reported her condition caused her severe emotional
distress. In light of the unsatisfactory results to her prior
repigmentation therapy and the extensive areas of involvement, the
patient desired depigmentation therapy. Of note is the absence of
any family history of vitiligo or autoimmune disorders.
The patient was photographed for documentation and then started
on 20% monobenzone cream with frequent follow up examinations
for progression of her therapy. The patient received 3 years of
treatment with highly satisfactory results and no side effects.
However, soon after termination of monobenzone treatment, the
patient noticed some repigmentation on her arms after sun exposure.
This progressed to involve areas on her chest and face. Unfortu
nately soon after this, the pharmaceutical manufacturer stopped
supplying monobenzone and no further supplies have been avail
able in America. The patient was then treated with hydroquinone
without satisfactory response. Numerous attempts have been made
to find alternative sources of monobenzone. So far this has been
unsuccessful.
Discussion
Definition
“Vitiligo is a disease of unknown origin which causes destruction
of melanocytes in the skin, mucous membranes, the eyes, and
occasionally in hairbulbs and in the ears. The loss of melanocytes
alters both structure and function of these organs.”
Incidence
Vitiligo affects between 0.066% to 8% of Americans.24It occurs
in all ethic groups and equally in males and females. Vitiligo tends
to be more noticeable in darker skinned ethnic groups. However,
there is no evidence to conclude that the incidence is any greater in
darker skinned people. Of additional interest is the age predomi
nance in vitiligo; 25% ofpatients develop vitiligo before 10 years of
age, 50% develop it before 20 years of age and 95% before the age
of 40.’ There is no literature to suggest any significant difference in
the incidence of vitiligo in Hawaii compared with the rest of the
country.
Pathophysiology
There are three widely accepted theories as to the etiology of
vitiligo, however, the precise pathophysiology of vitiligo is still
unknown and the subject of current research. The neural theory
supports the notion that depigmentation is due to melanocyte
destruction or inhibition of melanin production when a chemical
mediator is released at the nerve endings. Another theory explains
vitiligo as the result of destructiOn of melanocytes by tyrosine, dopa
and 5,6-dihydoxyindole which are all involved with the normal
production of melanin. It has been postulated that melanocytes have
a protective mechanism against their destruction, however, when
this is lost, the result is melanocyte damage and depigmentation.
The final theory ascribes vitiligo to an autoimmune dysfunction. Of
particular interest is the finding that there is a ten fold increase in
vitiligo in patients with autoimmune diseases.5-’3In addition, stud
ies by Naughton et al., and Gilhar et al.,have demonstrated antibod
ies against melonocytes in vitiligo patients.7”4
Differential Diagnosis
There are a number of other conditions of depigmentation that
may be confused with vitiligo. Usually a careful physical examina
tion and history is sufficient to distinguish vitiligo from other
causes. One of the most common of these is tinea versicolor, i.e.,
kane in Hawaiian. This can be readily ruled in or out by performing
a potassium hydroxide test on skin scrapings and looking for the
characteristic fungal hyphae under the microscope. Tinea, if diag
nosed, can be readily treated with any number of the antifungals
available to the clinician. Scieroderma and morphea can also be
readily ruled out by simple palpation of the lesions. Listed below are
some additional, conditions that the clinician should be aware of in
the differential diagnosis.
Diagnostic Criteria
Clinical Features
The diagnosis of vitiligo is almost exclusively made by examina
tion of the patient. Vitiligo is often first detected by patients when
they notice areas of depigmentation contrasting with normal darker
areas of their skin. In addition, hypopigmentation may also be
present. These patterns generally have well demarcated borders.
Commonly affected areas are the hands and body openings such as
the eyes, nostrils, mouth, nipples, umbilicus and genitalia. These
areas of vitiligo are usually bilateral and symmetrical. However, the
converse is also observed and any part of the body may be affected.
Other areas affected that have been reported are previous sites of
trauma and scarring.9”4In particularly fair skinned patients(type 11
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II) who may not have greatly contrasting areas of depigmentation,
a Wood’s lamp may prove helpful in assessing the involved areas.
While the diagnosis of vitiligo can generally be made by the history
and physical examination, further diagnostic tests may be helpful in
differentiated this condition from other disorders that are similar in
presentation. In addition, associated disorders such as thyroid
disorders, pernicious anemia, diabetes, or Addison’s disease may be
also detected by additional diagnostic tests.
A biopsy may be helpful in differentiating vitiligo and other
similarly presenting diseases — the histological features of vitiligo
are discussed in the next section. However, most patients do not
require a biopsy.’ Thyroid function tests maybe helpful in ruling out
an associated thyroid disorder. Further tests include antiparietal
cell, antithyroid(thyroglobulin and microsomal), and antinuclear
antibodies to rule out commonly associated autoimmune disorders.
Histology
In early vitiligo the only abnormality may be a decrease in the
number of melanocytes. In late stages there is a complete absence
of melanocytes. Additional features may be basilar vacuolopathy,
exocytosis of lymphocytes, spongiosis, and lymphohistiocytic in
However, often times these are not observed.
Current Treatment Modalities
There are two major ways to treat this disfiguring ailment. The
more preferable and widely used therapy is repigmentation. An
alternative in extensive vitiligo (>50%) or vitiligo that has failed
repigmentation therapy is depigmentation of the remaining melano
cytes.9IS These various methods have been well described in
numerous articles. In addition, on going research holds the promise
of additional treatment 16,I8,9
Repigmentation Therapy
This can be done by a variety of methods. However, the most
widely used and successful is PUVA(Psoralen UltraViolet A)
therapy.”6 The precise mechanism of action of psoralen is un
known. However, PUVA therapy has been observed to result in
melanocyte hypertrophy and proliferation in the residual follicular
melanocytes in the vitiliginous areas. Furthermore, melanocytes in
pigmented areas surrounding these lesions undergo similar changes.
This results in repigmentation when these stimulated melanocytes
migrate to the depigmented areas. Treatment may require up to 18
months and more than a hundred visits.9”6This requires consider
able patient motivation. However, 16-24 treatments will usually
produce some new pigmentation.’6Suitability of this treatment is
based on the patients motivation, concern for appearance, race, age,
and access to phototherapy facilities. In addition, eye disease, skin
cancer, lupus erythematosus, hepatic and cardiovascular diseases
are also screened for in the evaluation of appropriateness of PUVA
therapy for the patient. In general topical PUVA is used in patients
with less than 20% involvement of their skin. For patients with more
than 20% involvement, resistant to topical PUVA or children
younger than 10 years old, oral PUVA is used instead.’9”6A
common side effect of both topical and oral PUVA is photosensitiv
ity. Severe blistering may occur with sun exposure and the patient
must ensure adequate protection with a broad spectrum(UVA and
UVB) sunscreen. With good patient motivation and compliance
PUVA can produce excellent results with a minimum of side effects.
The long term effects of PUVA are excellent and the vast majority
of patients are able to avoid additional therapy.’5Artificial sources
of UVA are generally more preferable over natural sunlight. UVA
machines have better reliability and consistency compared with
natural sunlight UVA which varies according to atmospheric con
ditions, the season, time of day and various other factors. In
addition, the risk of overexposure and toxic side effects are greater
with natural sunlight UVA. Topical PUVA is a contraindication for
natural sunlight PUVA.’ PUVA therapy is not indicated for children
under 2 years of age. Unfortunately, despite generally good results,
some patients are resistant to PUVA. Another therapy option is
steroids. Topical, intralesional, and oral steroids all have been used
with partial to complete repigmentation ranging between 10% and
82%.16 Topical steroids are usually considered for the initial treat
ment ofvitiligo. They are also useful in the treatment ofchildren less
than 2 years old. Low potency steroids are used in younger children
whereas mid to high potency steroids are used in older children and
adults.’6Results may take several weeks to appear and side effects
of the treatment include atrophy, striae, and telangiectasias. More
over, the risk of immunosuppression and infection is a concern with
steroid therapy. In patients who are resistent to repigmentation or
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Table 1 —Differential Diagnosis
1. Discoid lupus Erythematosus
2. Idiopathic guttate hypomelanosis
3. Lichen scierosus et atrophicus
4. Morphea
5. Nevus anemicus
6. Piebladism
7. Pityriasis alba
8. Woolf’s syndrome
9. Tinea versicolor
10. Turberous sclerosis
11. Scleroderma
12. Waardenburg’s syndrome
13. Ziprkowski-Margois syndrome
14. Leukoderma
15. Hanson’s disease
16. Mycosis Fungoides
Table 2.—Repigmentation Therapies
Medical
1. Topical psoralen photochemotherapy
2. Oral psoralen photochemotherapy
3. Topical steroid therapy
4. Oral steroid therapy
5. lntralesional therapy
6. Cosmetics
7. Khellin and UVA
8. L-Phenylalanine and UVA
9. Immune modulators(cyclosporine, Anapsos, Isoprinosine)
Surgical
1. Dermabrasion and topical 5-FU.
2. Autologous epiderrnal grafts.
3. Tattooing
4. Autologous melanocyte transplants.
Table 3.—Depigmentation Therapy
Medical
1. Monobenzylether of hydroquinone
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Fig 4—Pretreatment with monobenzone: This
shows the results of depigmentation with
monobenzone to the neck.
Eating Right Can Help
Reduce the Risk of
Cancer
It can also help you reduce your weight.
And since a 12-year-old study shows that being 40% more overweight puts you at
high risk, it makes sense to follow these guidelines for healthy living! Eat plenty of
fruits and vegetables rich ifl vitamins A and C—oranges, cantaloupe, strawber
ries, peaches, apricots, broccoli, cauliflower, brussel sprouts, cabbage. Eat a
high-fiber, low-fat diet that includes whole-grain breads
and cereals such as oatmeal, bran and wheat. Eat lean
meats, fish, skinned poultry and low-tat dairy products.
Drunk alcoholic beverages only in moderation. For more CAPICER
information, call 1-800-ACS-2345. f SOCIETY
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Fig 1.—Pretreatment with monobenzone: This Fig 2.—Pretreatment with monobenzone: This
demonstrates extensive depigmentation of the shows extensive involvement of the anterior sur
arms, chest and neck. faces of the lower extremities.
Fig 3.—Pretreatment with monobenzone: This
shows extensive involvement of the posterior
surfaces of the lower extremities.
Fig 5.—Post-treatment with monobenzone: This Fig 6.—Post-treatment with monobenzone: This
demonstrates the results of depigmentation of the demonstrates the results of depigmentation of the
right arm following treatment. left arm following treatment.
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with such extensive lesions that neither PUVA nor the other
repigmentation therapies are appropriate, depigmentation of their
remaining melanocytes is another option.
Depigmentation Therapy
This is the treatment of choice in patients resistance to
repigmentation or with extensive(greater than 50% involvement of
skin) vitiligo. The only recommended treatment in depigmentation
therapy that has been shown to work effectively and produce
cosmetically acceptable results is monobenzone.”9”6Treatment is
usually started with 10% monobenzone twice a day. However,
therapy should be tailored to the individual patient. After 2 to 3
months the concentration is increased to 20% if no irritation occurs.
Initially the face and upper arms are treated first to limit systemic
effects. This is followed by application to the other affected areas.
Depending on the patient’s reaction to the treatment this may take
up to 2 or 3 years. After treatment is complete the patient is
completely depigmented and must take precautions against sun
exposure. Dermatitis and pruritus are the most commonly reported
side effects. However, they can be effectively controlled with
corticosteroids. In addition, serosis, alopecia, premature graying,
and ocular changes have also been reported in some patients.’6
While it is important to note that this treatment is generally consid
ered to be permanent, repigmentation can occur. Additional appli
cations of monobenzone to the repigmented areas are usually
sufficient to remove them.
Conclusion
For extensive vitiligo(involving more than 50% of the patient’s
body) or vitiligo unresponsive to repigmentation therapies, depig
mentation provides an excellent alternative treatment.9’6The side
effects are easily controlled and the results can be highly satisfac
tory. Unfortunately, the only effective medication, monobenzone,
is no longer available in the United States. Reintroduction of this
Addendum
Shortly after submission of this manuscript there was news that
20% benoquim(monbenezone) might soon be reintroduced to the
American market.
Credits
Special thanks to Dr Norman Goldstein for his assistance.
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Fig 8.—Repigmentation: This photograph demon
strates spontaneous repigmentation of the arms
following cessation of monobenzone therapy.
Fig 7.—Post-treatment with monobenzone: This
demonstrates the results of depigmentation of the
tower extremities (anterior surface).
Fig 9.—Repigmentation: This photograph shows
several small areas of repigmentation to the
anterior surfaces of the lower extremities follow
ing cessation of monobenzone therapy.
drug to help this selective group of vitiligo patients would be highly
desirable.
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